Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol adaptive dose-selection phase 3 trial in COPD
2006-001955-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Novartis. Primary endpoints: Superiority of indacaterol versus placebo on trough FEV1 at 12 weeks and Non-inferiority of indacaterol versus tiotropium on trough FEV1 at 12 weeks. Started Feb 2007; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-001955-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001955-37.